A Johnson & Johnson employee has accused the company of not making enough effort to get its workers a good deal for prescription drugs, and that employees overpaid for some generic drugs designated as specialty medications by millions of dollars, The Wall Street Journal’s Melanie Evans and Anna Wilde Mathews report. “This is the first suit of its kind that we’re aware of,” Elizabeth Mitchell, chief executive of the Purchaser Business Group on Health, which represents employers, said about the J&J lawsuit. “It definitely will not be the last.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Senate Health, Education, Labor & Pensions Committee holds a hearing
- U.S. sends offers for drugs selected for price negotiations, NY Times says
- Senate Health, Education, Labor & Pensions Committee holds an executive session
- Nanobiotixachieves $20M milestone payment from Johnson & Johnson subsidiary
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call